Comments on ICER’s Draft Evidence Report for Aducanumab for Alzheimer’s Disease

June 3, 2021

Alzheimer’s and dementia already afflict too many people, yet their prevalence is expected to more than double in the coming decades. Effective Alzheimer’s treatments will reduce the disease’s economic costs today and will significantly decrease the expected cost burdens of the disease in the future.

Read Comments

Categorized in: Analysis

◀ Next Post

Previous Post ►